Regeneron initiates study of REGN13335 for Pulmonary Arterial Hypertension
Regeneron Pharmaceuticals is conducting a clinical trial to evaluate the safety and efficacy of REGN13335 in adults with Pulmonary Arterial Hypertension (PAH).
Phase III
Cardiovascular / Pulmonary Arterial Hypertension
Status
Active
Sponsor
Regeneron
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
Portfolio teams should monitor REGN13335's trial outcomes as they could influence Regeneron's strategy in the PAH space and competitive positioning against existing therapies.
Why it matters
The initiation of the REGN13335 trial by Regeneron is significant as it introduces a potential new treatment in a competitive market dominated by established therapies. Monitoring the trial's outcomes is crucial for understanding Regeneron's positioning and potential shifts in market dynamics.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results on safety and efficacy, as well as data on antibody formation against REGN13335.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.